Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818936 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2PDK2HPGDLMNAGAA | |
| SCHEMBL612170 | 0.87 | CNR2 (0.56) | SMN1; SMN2PDK2HPGDKMT2A | |
| SCHEMBL27439170 | 0.87 | KMT2A (0.55) | SMN1; SMN2PDK2HPGDLMNAGAA | |
| SCHEMBL25822284 | 0.86 | KDM4E (0.51) | SMN1; SMN2PDK2HPGDLMNAGAA | |
| SCHEMBL25820387 | 0.85 | KDM4E (0.60) | SMN1; SMN2PDK2HPGDLMNAGAA | |
| SCHEMBL2208515 | 0.85 | CNR1 (0.52) | SMN1; SMN2PDK2HPGD | |
| SCHEMBL29818817 | 0.85 | CNR1 (0.52) | SMN1; SMN2PDK2HPGD | |
| SCHEMBL13959276 | 0.85 | FFAR1 (0.51) | HPGDGAAKMT2AMEN1RAB9A | |
| SCHEMBL2206953 | 0.83 | TAAR1 (0.50) | SMN1; SMN2PDK2KMT2AMEN1 | |
| SCHEMBL29818781 | 0.83 | TAAR1 (0.50) | SMN1; SMN2PDK2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SMN1; SMN2 39/4885PDK2 502/4885HPGD 110/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SMN1; SMN2 42/4885PDK2 496/4885HPGD 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.